"Targeting RNA Polymerase I in Ewing Sarcoma Therapy" by Alexis Bruce
 
Targeting RNA Polymerase I in Ewing Sarcoma Therapy

Targeting RNA Polymerase I in Ewing Sarcoma Therapy

Date

2-18-2025

Faculty Mentor

Le Su, Biology

Submission Type

Conference Proceeding

Location

11:45-11:55am | Houston Cole Library, 11th Floor

Description

Please note: no video is available for this presentation.

Ewing sarcoma is a rare and aggressive pediatric bone cancer with poor survival rates in patients, as low as in 30% in advanced or recurrent cases. There are limited treatment options, making molecularly-targeted therapy vital to explore. Through CRISPR scans of Ewing sarcoma cell lines, ribosome biogenesis was highlighted as a potential target. As RNA polymerase I is a key component of ribosome biogenesis, the cytotoxic ability of two RNA Polymerase I inhibitors, CX-5461 and BMH-21, were used on Ewing sarcoma cells. The efficacy of the drugs on two cell lines were determined via measuring cell viability, migration potential, and colony formation potential after drug treatments. RNA levels were measured after drug treatment to determine the level of inhibition of RNA polymerase I. The growth of multicellular spheroids that resemble tumors were treated and grown over time to show the growth of the cancer cells, as well as the cytotoxicity of the RNA Polymerase I inhibitors. This presentation details the results and efficacy of the two potential targeted therapies on Ewing sarcoma cell lines.

Keywords

student research, biology

Rights

This content is the property of Jacksonville State University and is intended for non-commercial use. Video and images may be copied for personal use, research, teaching or any "fair use" as defined by copyright law. Users are asked to acknowledge Jacksonville State University. For more information, please contact digitalcommons@jsu.edu.

Disciplines

Biology

Targeting RNA Polymerase I in Ewing Sarcoma Therapy

Share

COinS